•
Mar 31, 2020
Protalix Q1 2020 Earnings Report
Reported financial results for the first quarter ended March 31, 2020, and provided a business update on recent corporate and clinical developments.
Key Takeaways
Protalix reports a transformational first quarter in 2020, closing a $43.7 million private placement and submitting a BLA for PRX-102 after completing the Phase III BRIDGE study.
Closed a $43.7 million private placement.
Completed Phase III BRIDGE study.
Submitted BLA for PRX-102.
Adapted quickly to the changing environment despite the COVID-19 pandemic.
Protalix
Protalix
Forward Guidance
Protalix is positioned for long-term success and looks forward to continuing momentum through the rest of this year and into 2021.